Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity ...

Last week, it licensed a series of fibroblast activation protein (FAP) targeting agents from iTheranostics that can be used to image and potentially ... called Lu-PSMA-617, which improved survival ...

The ligand is linked to a radioactive isotope molecule that can either be used to image the tumour ... to buy targeted radioligand therapy Lu-PSMA-617 from Endocyte, shortly after encouraging ...

A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in 18F-DCFPyL Images of Veterans with Prostate Cancer PSMA PET Validates Higher Rates of Metastatic Disease for European ...

MH was clinical lead on 177Lu-PSMA therapy trial and with the assistance of RH provided access to validation images used in this study. All authors contributed to the review and authorization of the ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...

Telix Pharmaceuticals Ltd.’s prostate cancer PET imaging agent Illuccix has been approved by the Danish Medicines Agency.

In this connection, Federal Minister for Industries and Production Rana Tanveer Hussain on Tuesday held a meeting with the Pakistan Sugar Manufacturers Association (PSMA) mainly focused on ...